Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma
Trial Timeline
Mar 11, 2024 → Apr 1, 2034
NCT ID
NCT06151236About Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination is a phase 2 stage product being developed by Bristol Myers Squibb for Merkel Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06151236. Target conditions include Merkel Cell Carcinoma.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06288191 | Phase 2 | Recruiting |
| NCT06151236 | Phase 2 | Recruiting |
Competing Products
20 competing products in Merkel Cell Carcinoma